Type 1 diabetes: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• GLP-1 21
• SGLT2 12
• NRF2 0
• CTLA-4 0
• STAT3 0
• AKT 0
• GIP 2
• PD-1 0
• SIRT1 0
• CD40 0
• PPAR 0
• TP53 0
• JAK 1
• JNK 0
• mTOR 0
• NLRP3 1
• TLR4 0
• AMPK 0
• DPP-4 0
• IL-6 0
• TNF 0
• IL-1 0
• IL-17 0
• MAPK 0
• PI3K 0
• VEGF 1
• CD47 0
• HMGB1 0
• PD-L1 0
• ACE2 0
• BDNF 0
• CD19 0
• CD20 1
• CD38 0
• ERK 0
• FOXP3 0
• G6PD 0
• IL-13 0
• IL-4 0
• PCSK9 0
• RANKL 0
• STING 0
• TIGIT 0
• AR 0
• B7-H3 0
• CD22 0
• CTNNB1 0
• CXCR4 0
• EGFR 0
• GPX4 0
• HDAC 0
• HER2 0
• HER3 0
• HSP90 0
• IGF1R 0
• LAG-3 0
• METTL3 0
• MYC 0
• NMDA 0
• PDGFR 0

14 of 14+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-ERC

  Modeling islet inflammation in early-stage type 1 diabetes: T1DstartEd (T1Dstarted)

  The Hebrew University of Jerusalem· Jerusalem, Israel· EU contribution €2,796,250· until May 2032

• European Commission (Horizon Europe) · HORIZON-EIC-ACC

  The Inreda bi-hormonal blood glucose control pump: A beacon for high-risk diabetes patients, providing fully automated in disease management (DIABEACON)

  Inreda Diabetic Bv· Goor, Netherlands· EU contribution €2,499,414· until Jun 2028

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-GF

  Type 1 Diabetes Simulator with Adjunctive therapies - GLP1 (T1SIA)

  Universitat Politecnica de Valencia· Valencia, Spain· EU contribution €243,097· until Jan 2028· 2 countries

• European Commission (Horizon Europe) · HORIZON-ERC

  From harassing to harnessing beta-cells in type 1 diabetes (Beta-STEALTH)

  Academisch Ziekenhuis Leiden· Leiden, Netherlands· EU contribution €2,500,000· until Oct 2030

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Uncovering Protective Mechanisms in Pancreatic β-Cells to Enhance Their Survival in Type 1 Diabetes (Beta_cell_protection)

  Universite Libre de Bruxelles· Bruxelles, Belgium· EU contribution €200,400· until Jul 2027

5 of 9 running projects, newest first. Listed amounts together: €48.3m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Withdrawn

  Effect of GLP-1 on Microvascular Insulin Responses in Type 1 Diabetes

  NCT04133922· University of Virginia· Updated 22 Mar 2022

  “the study drug could not be obtained”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• Glycemic and Weight Loss Effects of GLP-1R Agonist Therapy in Subjects With Spinal Cord Injury and Type 2 Diabetes

  NCT06706284· Marzieh Salehi· Source

• A Clinical Trial Using Tirzepatide to Help Adults With Type 1 Diabetes Automatically Control Their Blood Sugar

  NCT07284511· McGill University Health Centre/Research Institute of the McGill University Health Centre· Source

• GLP-1Ra Impact on Metabolic Outcomes in Stage 2 T1DM While Receiving Teplizumab

  NCT06338553· Vanderbilt University Medical Center· Source

• Semaglutide Treatment in Type 1 Diabetes

  NCT06909006· Nordsjaellands Hospital· Source

• Tirzepatide for the Treatment of Concurrent Type 1 Diabetes and Overweight or Obesity

  NCT06180616· Royal North Shore Hospital· Source

• A Clinical Trial to Evaluate The Effects of Semaglutide and Empagliflozin Combined to Automated Insulin Delivery on Diabetes Control in Adults Living With Type 1 Diabetes

  NCT06894784· McGill University Health Centre/Research Institute of the McGill University Health Centre· Source

• Weekly Subcutaneous Semaglutide as Adjunct to Closed-loop Therapy in Type 1 Diabetes Care

  NCT05205928· McGill University Health Centre/Research Institute of the McGill University Health Centre· Source

• Alleviating Carbohydrate Counting for Patients with Type-1 Diabetes Using a Closed Loop System with Weekly Subcutaneous Semaglutide

  NCT06387199· McGill University Health Centre/Research Institute of the McGill University Health Centre· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 10
• Organoids 4
• Mendelian Randomization Analysis 35
• CRISPR-Cas Systems 5
• Gene Expression Profiling 34
• Sequence Analysis, RNA 3
• Whole Genome Sequencing 1
• Exome Sequencing 3
• Proteomics 20
• Metabolomics 15
• Mass Spectrometry 4
• Flow Cytometry 12
• Immunohistochemistry 16
• Positron-Emission Tomography 3
• Magnetic Resonance Imaging 33
• Machine Learning 31
• Deep Learning 10
• Cohort Studies 158
• Genome-Wide Association Study 54

• Baseline Serum Metabolites as Predictors of Teplizumab Response in Individuals With Type 1 Diabetes.

  Diabetes, Nov 2026

• Research progress and application prospects of multi-omics integration strategies in precision risk stratification of type 1 diabetes mellitus.

  Front Immunol, Aug 2026

• Metabolomic signatures of glycemic control in type 1 diabetes: insights from continuous glucose monitoring.

  J Endocrinol Invest, Jul 2026

• Metabolomic profile differs between LADA and type 1 diabetes identifying tryptophan metabolism as a pathway involved in the heterogeneity of autoimmune diabetes.

  Diabetologia, Jun 2026

• Integrated metabolomics and computational pharmacology to reveal the complementary antidiabetic mechanisms of Tithonia-Curcuma-Moringa (TCM) polyherbal.

  Comput Biol Chem, May 2026

• Effect of statins and ACE inhibitors on the metabolome in the Adolescent Type 1 Diabetes cardio-renal Intervention Trial (AdDIT) cohort.

  Sci Rep, Apr 2026

• ToF-SIMS metabolomic analysis of urinary extracellular vesicles to identify potential markers for diabetic kidney disease in type 1 diabetes.

  Adv Med Sci, Apr 2026

• Proteomics and metabolomics biomarkers for predicting the onset and progression of diabetic complications: A systematic review and bioinformatics integration.

  Metabolism, Mar 2026

• Metabolic Effects of Isoenergetic High-Intensity Interval Training and Moderate-Intensity Continuous Training in Adults with Type I Diabetes.

  Med Sci Sports Exerc, Jan 2026

• Gut Microbiota Modulation by Abelmoschus manihot (L.) Improves Circulating Metabolites and Alleviates Diabetic Nephropathy in db/db Mice.

  Biomed Res Int, Jan 2026

See which targets of this disease your abstract mentions, and go to the people working on them.